|
Lancet Oncology |
TOMAS: an open-label, phase 1b study from the Italian Sarcoma Group. |
 |
|
Lancet Oncology |
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis |
 |
|
Cancer Discovery |
MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer |
 |
|
Nature |
The genomic landscape of response to EGFR blockade in colorectal cancer |
 |
|
Nat Med. |
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. |
 |
|
Nat Genet. |
Stromal contribution to the colorectal cancer transcriptome. |
 |
|
Science Tran. Med. |
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies |
 |
|
Lancet Oncol. |
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. |
 |
|
Cancer Discov. |
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. |
 |
|
Cancer Res. |
MET-Mediated Resistance to EGFR Inhibitors: An Old Liaison Rooted in Colorectal Cancer Stem Cells. |
 |
